
Rami Manochakian/X
Jun 1, 2025, 08:04
Rami Manochakian: Big News Released by Summit Therapeutics on HARMONi Phase III Global Trial at ASCO 2025
Rami Manochakian, Vice President of the North American Neuroendocrine Tumor Society, shared a post on X:
“Hot Off The Press
Big News Release by Summit Therapeutics in time with ASCO 25.
Results from the HARMONi Phase III global trial evaluating:
Ivonescimab + Chemo vs Chemo in patients with advanced EGFR+ NSCLC after progression on 3rd gen TKI:Statistically significant and clinically meaningful Improvement in progression-free survival.
PFS HR: 0.52
OS positive trend: HR 0.79″
Read more about HARMONi Study.
More posts featuring Rami Manochakian on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 2, 2025, 18:07
Jun 2, 2025, 18:00
Jun 2, 2025, 17:43
Jun 2, 2025, 17:18
Jun 2, 2025, 17:06
Jun 2, 2025, 15:40
Jun 2, 2025, 15:37
Jun 2, 2025, 15:20